GBM Agile Trial

Brief description of study

The purpose of the research study is to evaluate multiple investigational treatments for either newly diagnosed or recurrent brain tumors to determine if any of these study treatments improve overall survival as compared to standard treatments. Investigational means that these are new treatments sometimes called “study drugs” and are not approved by the Food and Drug Administration (FDA) to be used for your type of cancer. The investigational treatments in this study have been previously tested in people. If you choose to participate in the study, you will be randomized like the flipping of a coin or the rolling of dice, to determine which treatment you will receive.


Clinical Study Identifier: s19-00633
ClinicalTrials.gov Identifier: NCT03970447
Principal Investigator: Erik P. Sulman.
Other Investigators: Minerva A Utate, Lynda J Boulio, Joshua S. Silverman, Sylvia Amor Tenefrancia Crispino, Maria Del Pilar Guillermo Prieto Eibl.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.